SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CS 2100

Item No. 14396

CAS Registry No.: 913827-99-3
Formal Name: 1-[[4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]-3-azetidinecarboxylic acid
MF: $C_{25}H_{23}N_3O_4S$
FW: 461.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CS 2100 is supplied as a solid. A stock solution may be made by dissolving the CS 2100 in the solvent of choice, which should be purged with an inert gas. CS 2100 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

CS 2100 is a sphingosine-1-phosphate receptor 1 ($S1P_1$) agonist.[1,2] It selectively induces GTPγS binding in CHO-K1 cells expressing human or rat $S1P_1$ (EC_{50}s = 4 and 1.5 nM, respectively) over those expressing human or rat $S1P_3$ (EC_{50}s = >20 and 7.4 µM, respectively).[2] CS 2100 (0.1 and 1 mg/kg) transiently reduces blood lymphocyte levels in rats with the levels returning to baseline within 24-48 hours. It reduces hind paw volume in a rat model of adjuvant-induced arthritis (ID_{50} = 0.44 mg/kg). CS 2100 (0.3 and 1 mg/kg) also decreases severity in a mouse model of experimental autoimmune encephalomyelitis (EAE).

References

1. Nakamura, T., Asano, M., Sekiguchi, Y., *et al*. Synthesis and evaluation of CS-2100, a potent, orally active and $S1P_3$- sparing $S1P_1$ agonist. *Eur. J. Med. Chem.* **51**, 92-98 (2012).
2. Nakamura, T., Asano, M., Sekiguchi, Y., *et al*. Discovery of CS-2100, a potent, orally active and $S1P_3$-sparing $S1P_1$ agonist. *Bioorg. Med. Chem. Lett.* **22(4)**, 1788-1792 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM